Ads
related to: what is daratumumab prescribed for in adults dosage guide- DARZALEX® Side Effects
Find Information About Side Effects
Patients May Experience
- Read Patient Stories
Learn About the Treatment Journey
From Real Patients & Caregivers
- Preparing For Treatment
Watch a Video About What to Expect
Before, During, & After Treatment
- About DARZALEX®
Learn About a Treatment Method and
How DARZALEX® Works
- Cost Support Options
Learn About Potential Cost Support
Options Through Janssen CarePath
- Questions for Your Doctor
Find a List Of Questions for You to
Ask Your Healthcare Provider
- DARZALEX® Side Effects
Search results
Results From The WOW.Com Content Network
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38 , [ 7 ] which is overexpressed in multiple myeloma cells. [ 8 ]
It was approved for use in the United States in May 2020. [2] [7] [8]Efficacy of daratumumab and hyaluronidase-fihji (monotherapy) was evaluated in the COLUMBA trial (NCT03277105), an open-label non-inferiority trial randomizing 263 participants to daratumumab and hyaluronidase-fihj and 259 to intravenous daratumumab (daratumumab IV). [2]
Drug Manufacturer Indication Adagrasib: In combination with cetuximab for the treatment of adults with KRAS G12C mutated locally advanced or metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy [2] Arimoclomol
Prescribed daily dose (PDD) is the usual dose of medication calculated by looking at a group of prescriptions for the medication in question. [1] At times the PDD needs to be related to the condition being treated .
Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, [5] a type of white blood cell cancer, [6] in combination with other drugs. It is taken by mouth in the form of capsules.
Previously considered a promising drug, the FDA granted olaratumab fast track designation, breakthrough therapy designation and priority review status. In October 2016, the US FDA issued an accelerated approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft-tissue sarcoma, based on the same study.
Ads
related to: what is daratumumab prescribed for in adults dosage guide